The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Apr 2021
Randomized Controlled TrialEffect of early and late prenatal vitamin D and maternal asthma status on offspring asthma or recurrent wheeze.
Childhood asthma developmental programming is complex. Maternal asthma is a strong risk factor for childhood asthma, whereas vitamin D (VD) has emerged as a modifiable prenatal exposure. ⋯ This study implies a protective role for VD sufficiency throughout pregnancy, particularly in attenuating the risk conferred by maternal asthma on childhood asthma or recurrent wheeze development.
-
J. Allergy Clin. Immunol. · Sep 2020
Randomized Controlled Trial Clinical TrialUnderstanding the asthmatic response to an experimental rhinovirus infection: Exploring the effects of blocking IgE.
Rhinovirus frequently causes asthma exacerbations among children and young adults who are allergic. The interaction between allergen and rhinovirus-induced symptoms and inflammation over time is unclear. ⋯ LRTSs and blood eosinophil counts were augmented and lung function was reduced among allergic asthmatics early after rhinovirus inoculation but increased late in the infection during symptom resolution. The effect of administering omalizumab on the response to rhinovirus was most pronounced during the early/innate phase of the infection.
-
J. Allergy Clin. Immunol. · Jul 2020
Randomized Controlled Trial Multicenter StudyRuxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.
Accumulating evidence proposed Janus-associated kinase (JAK) inhibitors as therapeutic targets warranting rapid investigation. ⋯ Although no statistical difference was observed, ruxolitinib recipients had a numerically faster clinical improvement. Significant chest computed tomography improvement, a faster recovery from lymphopenia, and favorable side-effect profile in the ruxolitinib group were encouraging and informative to future trials to test efficacy of ruxolitinib in a larger population.
-
J. Allergy Clin. Immunol. · Mar 2020
Randomized Controlled TrialUpadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.
Atopic dermatitis is a chronic inflammatory skin disease characterized by pruritic skin lesions. ⋯ A dose-response relationship was observed for upadacitinib efficacy; the 30-mg once-daily dose showed the greatest clinical benefit. Dose-limiting toxicity was not observed.
-
J. Allergy Clin. Immunol. · Jan 2020
Randomized Controlled Trial Multicenter StudyPhase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.
Nemolizumab targets the IL-31 receptor α subunit involved in atopic dermatitis (AD) pathogenesis. ⋯ Nemolizumab resulted in rapid and sustained improvements in cutaneous signs of inflammation and pruritus in patients with AD, with maximal efficacy observed at 30 mg. Nemolizumab had an acceptable safety profile.